PULSION recieves US approval for ICG-PULSION
High demand of ICG in US market expected/ Commercialization in US still in 2007/ Substantial growth with ICG-PULSION
This release was saved as a PDF file. Please click on the "view PDF" link to display this report.
You need the free Adobe Reader in order to display this release.Download Adobe Reader
PULSION Medical Systems SE
PULSION Medical Systems AG, founded in 1990, has become one of the leading specialists for intelligent medical diagnosis and therapy management systems and has been listed on the Stock Exchange in Frankfurt since 2001. The repeated development of innovative product lines in the medtech field is the basis for creation and expansion of the attractive disposable business with sterile products and pharmaceuticals.
The business unit PULSION Critical Care covering intensive care medicine, perioperative medicine and emergency medicine focuses on the management of cardiovascular and organ functions of critically ill patients. Products and activities of the business unit PULSION Perfusion are directed at the diagnosis and therapy management of organ and tissue perfusion in ophthalmology, surgery and hepatology.
PULSION products are marketed worldwide via own sales channels or secondary distribution. All products are certified with the CE mark which is basis for marketing in the EU and some other countries. The US-American FDA approval and the Japanese market approval have been issued for selected product lines.
Further information about PULSION is available at www.pulsion.com.
PULSION Medical Systems AG
ISIN DE0005487904 Equity capital: Euro 9,577,302 divided into no-par-value euro 1 individual share certificates